4/7
09:47 am
gild
Gilead Sciences (GILD) had its price target raised by Royal Bank Of Canada from $118.00 to $123.00. They now have a "sector perform" rating on the stock.
Low
Report
Gilead Sciences (GILD) had its price target raised by Royal Bank Of Canada from $118.00 to $123.00. They now have a "sector perform" rating on the stock.
4/7
08:30 am
gild
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
Low
Report
Gilead to Acquire Tubulis Adding Potentially Best-in-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline
4/4
08:30 am
gild
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets [Yahoo! Finance]
Low
Report
Galapagos NV (GLPG) Signs Agreement with Gilead on Ouro Medicines Assets [Yahoo! Finance]
4/2
02:38 am
gild
A Look At Gilead Sciences (GILD) Valuation After Recent Mixed Share Price Performance [Yahoo! Finance]
Low
Report
A Look At Gilead Sciences (GILD) Valuation After Recent Mixed Share Price Performance [Yahoo! Finance]
4/1
04:13 pm
gild
Gilead Extends Tender Offer to Acquire Arcellx
Low
Report
Gilead Extends Tender Offer to Acquire Arcellx
3/28
03:53 am
gild
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks [Seeking Alpha]
Low
Report
Gilead Sciences: Caution After A Re-Rating Amidst New Concentration Risks [Seeking Alpha]
3/27
08:05 pm
gild
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance]
Low
Report
Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic? [Yahoo! Finance]
3/27
04:52 pm
gild
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) [Seeking Alpha]
Low
Report
Gilead: Why The 'Immune System Company' Pivot Is No Longer A Bargain (Downgrade) [Seeking Alpha]
3/26
09:02 pm
gild
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline [Yahoo! Finance]
Low
Report
Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline [Yahoo! Finance]
3/24
08:03 pm
gild
Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal [Yahoo! Finance]
Low
Report
Gilead Strengthens Inflammation Portfolio With Ouro Medicines Deal [Yahoo! Finance]
3/24
07:13 pm
gild
Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal [Yahoo! Finance]
Low
Report
Gilead Eyes $2.2 Billion Autoimmune Push With Ouro Deal [Yahoo! Finance]
3/24
12:14 pm
gild
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases [Yahoo! Finance]
Low
Report
Gilead, with Ouro deal, wagers $1.7B on bispecifics for autoimmune diseases [Yahoo! Finance]
3/24
10:47 am
gild
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio [Yahoo! Finance]
Low
Report
Gilead Sciences to acquire Ouro Medicines, expanding autoimmune therapy portfolio [Yahoo! Finance]
3/23
06:42 pm
gild
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases [Yahoo! Finance]
Low
Report
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases [Yahoo! Finance]
3/23
06:15 pm
gild
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
Low
Report
Gilead Sciences to Acquire Ouro Medicines to Advance First in Class T Cell Engager Program for Autoimmune Diseases
3/18
06:49 am
gild
3 Reasons to Avoid GILD and 1 Stock to Buy Instead [Yahoo! Finance]
Low
Report
3 Reasons to Avoid GILD and 1 Stock to Buy Instead [Yahoo! Finance]
3/17
09:00 am
gild
Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast Cancer
Low
Report
Manta Cares and Gilead Sciences Collaborate to Support Patients Navigating Metastatic Lung and Breast Cancer
3/17
06:28 am
gild
3 Cash-Flow Machines Investors May Want Heading Into 2026 [Yahoo! Finance]
Low
Report
3 Cash-Flow Machines Investors May Want Heading Into 2026 [Yahoo! Finance]
3/17
05:48 am
gild
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth [Yahoo! Finance]
Low
Report
Gilead Sciences at Barclays: CFO touts YEZTUGO launch, Arcellx deal and “long cycle” growth [Yahoo! Finance]
3/15
05:59 pm
gild
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades [Yahoo! Finance]
Low
Report
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades [Yahoo! Finance]
3/13
11:38 am
gild
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]
Low
Report
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise? [Yahoo! Finance]
3/12
09:11 am
gild
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy [Yahoo! Finance]
Low
Report
Pharma Leaders Discuss Managing Revenue Management System Updates at Model N Rainmaker Panel Hosted by RevSavvy [Yahoo! Finance]
3/10
09:00 am
gild
Gilead Sciences (GILD) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $180.00 price target on the stock.
Low
Report
Gilead Sciences (GILD) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating and a $180.00 price target on the stock.
3/8
11:10 pm
gild
???????????????????? :???????????????2035????2388?2000????????????????????(CAGR)6.0%???????????? [CNET News]
Low
Report
???????????????????? :???????????????2035????2388?2000????????????????????(CAGR)6.0%???????????? [CNET News]
3/7
07:03 pm
gild
Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run [Yahoo! Finance]
Low
Report
Is It Time To Reassess Gilead Sciences (GILD) After Its Strong Share Price Run [Yahoo! Finance]